LONGER-TERM FOLLOW-UP OF A PHASE 1 STUDY OF PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) LEUKEMIAS

被引：0

作者：

Cortes, J. ^{[1
]}

Talpaz, M. ^{[2
]}

Kantarjian, H. M. ^{[1
]}

Shah, N. P. ^{[3
]}

Bixby, D. ^{[2
]}

Flinn, I. W. ^{[4
]}

O'Hare, T. ^{[5
]}

Hu, S. ^{[6
]}

Rivera, V. ^{[6
]}

Clackson, T. ^{[6
]}

Turner, C. ^{[6
]}

Haluska, F. ^{[6
]}

Druker, B. J. ^{[7
]}

Deininger, M. W. ^{[5
]}

Mauro, M. J. ^{[7
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[3] Univ Calif San Francisco, San Francisco, CA 94143 USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[6] ARIAD Pharmaceut Inc, Cambridge, MA USA

[7] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P895

引用

页码：335 / 335

页数：1

共 50 条

[41] Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome-positive (Ph plus ) leukemia: Phase 1/2 study update.
Gambacorti-Passerini, Carlo
Lipton, Jeffrey Howard
Hochhaus, Andreas
Kota, Vamsi K.
Baccarani, Michele
Durrant, Simon
Assouline, Sarit E.
Kim, Dong-Wook
Bruemmendorf, Tim H.
Leip, Eric
An, Fiona
Aguiar, Jean
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[42] A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)
Nguyen, Daniel
Jabbour, Elias
Short, Nicholas
Issa, Ghayas C.
Yilmaz, Musa
Daver, Naval
Pemmaraju, Naveen
Chien, Kelly S.
Masarova, Lucia
Ravandi, Farhad
Jain, Nitin
Deen, Wuliamatu
Zhao, Min
Loiselle, Christopher
Waller, Lourdes
Banks, Glenda
Garris, Rebecca
Kantarjian, Hagop
BLOOD, 2022, 140 : 6127 - 6129
[43] Low-intensity chemotherapy (mini-HCVD) and ponatinib followed by blinatumomab (blina) and ponatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL): A phase II study
Nasr, Lewis Fady
Jabbour, Elias
Haddad, Fadi
Short, Nicholas James
Macaron, Walid
Nasnas, Cedric Christophe
Zoghbi, Marianne
Issa, Ghayas C.
Yilmaz, Musa
Daver, Naval Guastad
Pemmaraju, Naveen
Masarova, Lucia
Ravandi, Farhad
Jain, Nitin
Deen, Wuliamatu
Loiselle, Christopher
Waller, Lourdes
Banks, Glenda
Garris, Rebecca
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[44] Bosutinib (BOS) for previously treated patients with Philadelphia chromosome-positive (Ph plus ) leukemia: ≥8-year update of a phase 1/2 study
Bruemmendorf, T. H.
Cortes, J. E.
Schafhausen, P.
Kindler, T.
Saussele, S.
Mueller, M. C.
Goh, Y. T.
Yilmaz, M.
Klisovic, R. B.
Purcell, S.
Viqueira, A.
Leip, E.
Gambacorti-Passerini, C.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 74 - 74
[45] First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).
Jabbour, Elias
Kantarjian, Hagop M.
Aldoss, Ibrahim
Montesinos, Pau
Leonard, Jessica Taft
Gomez-Almaguer, David
Baer, Maria R.
Gambacorti-Passerini, Carlo
McCloskey, James
Minami, Yosuke
Papayannidis, Cristina
Geraldo Rocha, Vanderson
Rousselot, Philippe
Vachhani, Pankit
Wang, Eunice S.
Wang, Bingxia
Hennessy, Meliessa
Vorog, Alexander
Patel, Niti
Ribera, Josep-Maria
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36_SUPPL) : 398868 - 398868
[46] First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).
Jabbour, Elias
Kantarjian, Hagop M.
Aldoss, Ibrahim
Montesinos, Pau
Leonard, Jessica Taft
Gomez-Almaguer, David
Baer, Maria R.
Gambacorti-Passerini, Carlo
McCloskey, James
Minami, Yosuke
Papayannidis, Cristina
Rocha, Vanderson Geraldo
Rousselot, Philippe
Vachhani, Pankit
Wang, Eunice S.
Wang, Bingxia
Hennessy, Meliessa
Vorog, Alexander
Patel, Niti
Ribera, Josep-Maria
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[47] Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): PhALLCON Study
Jabbour, Elias
Martinelli, Giovanni
Vignetti, Marco
Kantarjian, Hagop
Gomez-Almaguer, David
Minami, Yosuke
Dombret, Herve
Hennessy, Meliessa
Vorog, Alexander
Wang, Bingxia
Ribera, Josep-Maria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S269 - S269
[48] Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)
Lee, Hun Ju
Kantarjian, Hagop M.
Thomas, Deborah A.
Faderl, Stefan
Koller, Charles
Ferrajoli, Alessandra
Jabbour, Elias
Garris, Rebecca
Kebriaei, Partow
Champlin, Richard
Borthakur, Gautam
Wierda, William G.
Burger, Jan A.
Cortes, Jorge E.
O'Brien, Susan
Ravandi, Farhad
BLOOD, 2011, 118 (21) : 655 - 656
[49] A phase I study of INNO-406 in patients with advanced Philadelphia (Ph plus) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors
Kantarjian, Hagop M.
Cortes, Jorge
Le Coutre, Philipp
Nagler, Arnon
Pinilla, Javier
Hochhaus, Andreas
Jones, Dan
Craig, Adam R.
Carroll, Eileen
Ottmann, Oliver G.
BLOOD, 2007, 110 (11) : 144A - 144A
[50] Long-Term Follow-up of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients After Stem Cell Mobilisation Under Imatinib
Kim, Theo D.
Schwarz, Michaela
Kreuzer, Karl-Anton
Kaeda, Jaspal
Movassaghi, Kamran
Grille, Peggy
Daniel, Peter
Doerken, Bernd
le Coutre, Philipp
BLOOD, 2010, 116 (21) : 1400 - 1400

← 1 2 3 4 5 →